Evaluating the activity of temsirolimus in neuroendocrine cancer

Por O'Donnell, P H, Ratain, M J
Publicado em 2007

Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours

Por Goh, B C, Vokes, E E, Joshi, A, Ratain, M J
Publicado em 2002

Pharmacogenetic Pathway Analysis of Irinotecan

Por Rosner, G. L., Panetta, J. C., Innocenti, F., Ratain, M. J.
Publicado em 2008

Nonlinear Population Pharmacokinetics of Sirolimus in Patients With Advanced Cancer

Por Wu, K, Cohen, E E W, House, L K, Ramírez, J, Zhang, W, Ratain, M J, Bies, R R
Publicado em 2012

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN...

Por Iyer, L, King, C D, Whitington, P F, Green, M D, Roy, S K, Tephly, T R, Coffman, B L, Ratain, M J
Publicado em 1998

A Phase I study of Sirolimus and Bevacizumab in Patients with Advanced Malignancies

Por Cohen, E.E.W., Sharma, M.R., Janisch, L., Llobrera, M., House, L., Wu, K., Ramirez, J., Fleming, G.F., Stadler, W.M., Ratain, M.J.
Publicado em 2011

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado em 2006